吉非替尼联合TP方案治疗晚期肺癌的疗效及对血清炎性因子和免疫功能指标的影响

Efficacy of gefitinib combined with TP scheme in the treatment of advanced lung cancer and its impact on serum inflammatory factors and immune function indicators

目的 观察吉非替尼联合TP方案治疗晚期肺癌的疗效及对血清炎性因子和免疫功能指标的影响。方法 选取2020年12月—2021年12月龙岩市第二医院收治的晚期肺癌确诊患者200例,采用随机数字表法分为观察组和对照组,各100例。对照组予常规TP方案治疗,观察组在对照组基础上加用吉非替尼片治疗,2组均治疗1个月。比较2组患者近期疗效,治疗前后炎性因子[肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白介素-6(IL-6)]、免疫功能指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))变化及不良反应。结果 观察组患者客观缓解率(ORR)为80.00%,高于对照组的58.00%(χ^(2)=11.314,P=0.001);治疗1个月后,2组患者TNF-α、CRP、IL-6水平及CD8^(+)均较治疗前下降,CD4^(+)、CD4^(+)/CD8^(+)均较治疗前升高,且观察组下降或升高的程度大于对照组(P均<0.01);观察组与对照组不良反应总发生率(19.00%vs. 18.00%)比较差异无统计学意义(χ^(2)=0.033,P=0.856)。结论 吉非替尼联合TP方案治疗晚期肺癌患者的效果理想,对患者血清炎性因子和免疫功能指标具有积极影响,且用药安全风险并未增加。

Objective To observe the efficacy of gefitinib combined with TP scheme in the treatment of advanced lung cancer and its impact on serum inflammatory factors and immune function indicators.Methods A total of 200 confirmed patients with advanced lung cancer admitted to Longyan Second Hospital from December 2020 to December 2021 were selected.All patients were divided into observation group and control group using random number table method,with 100 cases in each group.The control group was treated with conventional TP scheme,while the observation group was treated with gefitinib tablets in addition to the control group.Both groups were treated for 1 month.The short-term efficacy,changes of inflammatory factors and immune function indexes before and after treatment,and the occurrence of adverse reactions in the two groups were compared.Results The objective response rate(ORR)of patients in the observation group was 80.00%,higher than 58.00%in the control group(χ^(2)=11.314,P=0.001).After 1 month of treatment,the levels of TNF-α,CRP,IL-6,and CD8^(+)in both groups decreased compared to before treatment,while CD4^(+)and CD4^(+)/CD8^(+)increased compared to before treatment.The degree of decrease or increase in the observation group was greater than that in the control group(P<0.01).There was no statistically significant difference in the total incidence of adverse reactions between the observation group and the control group(19.00%vs.18.00%,χ^(2)=0.033,P=0.856).Conclusion The efficacy of gefitinib combined TP scheme in the treatment of advanced lung cancer patients is ideal,which has a positive impact on patients′serum inflammatory factors and immune function indicators,and the safety risk of medication has not increased.